Literature DB >> 27240592

Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells.

Song Gao1, Liancheng Zhu1, Huilin Feng1, Zhenhua Hu1,2, Shan Jin1, Zuofei Song1,3, Dawo Liu1, Juanjuan Liu1, Yingying Hao1, Xiao Li1, Bei Lin4.   

Abstract

The aim of this study was to identify differentially expressed genes (DEGs) in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian cancer cells. Human whole-genome oligonucleotide microarrays were used to determine whether gene expression profile may differentiate the epithelial ovarian cell line Caov-3 transfected with FUT1 from the empty plasmid-transfected cells. Quantitative real-time PCR and immunohistochemical staining validated the microarray results. Gene expression profile identified 215 DEGs according to the selection criteria, in which 122 genes were upregulated and 93 genes were downregulated. Gene Ontology (GO) and canonical pathway enrichment analysis were applied, and we found that these DEGs are involved in BioCarta mammalian target of rapamycin (mTOR) pathway, BioCarta eukaryotic translation initiation factor 4 (EIF4) pathway, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in cancer. Interaction network analysis predicted genes participating in the regulatory connection. Highly differential expression of TRIM46, PCF11, BCL6, PTEN, and FUT1 genes was validated by quantitative real-time PCR in two cell line samples. Finally, BCL6 and Lewis Y antigen were validated at the protein level by immunohistochemistry in 103 paraffin-embedded ovarian cancer tissues. The identification of genes in response to FUT1 may provide a theoretical basis for the investigations of the molecular mechanism of ovarian cancer.

Entities:  

Keywords:  BCL6; Epithelial ovarian carcinoma; FUT1; Gene expression profile; α1,2-Fucosyl transferase

Mesh:

Substances:

Year:  2016        PMID: 27240592     DOI: 10.1007/s13277-016-5080-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  55 in total

1.  Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers.

Authors:  Salah-Eddine Bentebibel; Nathalie Schmitt; Jacques Banchereau; Hideki Ueno
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-01       Impact factor: 11.205

2.  A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma.

Authors:  Oren Smaletz; Maria D P E Diz; Claudio C do Carmo; Jorge Sabbaga; Geraldo F Cunha-Junior; Sergio J Azevedo; Fernando C Maluf; Carlos H Barrios; Ronaldo L Costa; Ana G Fontana; Vivian Madrigal; Alberto J Wainstein; Fernanda P Yeda; Venâncio A Alves; Ana M Moro; Roberto Blasbalg; Andrew M Scott; Eric W Hoffman
Journal:  Gynecol Oncol       Date:  2015-05-27       Impact factor: 5.482

3.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Authors:  Charles E Massie; Andy Lynch; Antonio Ramos-Montoya; Joan Boren; Rory Stark; Ladan Fazli; Anne Warren; Helen Scott; Basetti Madhu; Naomi Sharma; Helene Bon; Vinny Zecchini; Donna-Michelle Smith; Gina M Denicola; Nik Mathews; Michelle Osborne; James Hadfield; Stewart Macarthur; Boris Adryan; Scott K Lyons; Kevin M Brindle; John Griffiths; Martin E Gleave; Paul S Rennie; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

4.  Expression and correlation of Lewis y antigen and TGF-β1 in ovarian epithelial carcinoma.

Authors:  Sheng-Tan Wang; Juan-Juan Liu; Chang-Zhi Wang; Bei Lin; Ying-Ying Hao; Yi-Fei Wang; Song Gao; Yue Qi; Shu-Lan Zhang; Masao Iwamori
Journal:  Oncol Rep       Date:  2011-12-01       Impact factor: 3.906

5.  Lewis Y regulates signaling molecules of the transforming growth factor β pathway in ovarian carcinoma-derived RMG-I cells.

Authors:  Fei-Fei Li; Juan-Juan Liu; Da-Wo Liu; Bei Lin; Ying-Ying Hao; Jian-Ping Cong; Lian-Cheng Zhu; Song Gao; Shu-Lan Zhang; Masao Iwamori
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

6.  Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways.

Authors:  Dawo Liu; Juanjuan Liu; Bei Lin; Shuice Liu; Rui Hou; Yingying Hao; Qing Liu; Shulan Zhang; Masao Iwamori
Journal:  Int J Mol Sci       Date:  2012-01-16       Impact factor: 6.208

7.  The stimulation of IGF-1R expression by Lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma.

Authors:  Dawo Liu; Juanjuan Liu; Changzhi Wang; Bei Lin; Qing Liu; Yingying Hao; Shulan Zhang; Masao Iwamori
Journal:  Int J Mol Sci       Date:  2011-10-14       Impact factor: 5.923

8.  Development and use of the Cytoscape app GFD-Net for measuring semantic dissimilarity of gene networks.

Authors:  Juan J Diaz-Montana; Norberto Diaz-Diaz
Journal:  F1000Res       Date:  2014-07-01

9.  Elevated levels of Lewis y and integrin α5β1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma.

Authors:  Zhenhua Hu; Song Gao; Jian Gao; Rui Hou; Chuan Liu; Juanjuan Liu; Beibei Li; Dawo Liu; Shulan Zhang; Bei Lin
Journal:  Int J Mol Sci       Date:  2012-11-23       Impact factor: 5.923

10.  Malignant and nonmalignant gene signatures in squamous head and neck cancer.

Authors:  Maria J Worsham; Mei Lu; Kang Mei Chen; Josena K Stephen; Shaleta Havard; Vanessa P Schweitzer
Journal:  J Oncol       Date:  2012-04-12       Impact factor: 4.375

View more
  2 in total

1.  Human Epididymis Protein 4 and Lewis y Enhance Chemotherapeutic Resistance in Epithelial Ovarian Cancer Through the p38 MAPK Pathway.

Authors:  Jian Gao; Liancheng Zhu; Huiyu Zhuang; Bei Lin
Journal:  Adv Ther       Date:  2021-11-05       Impact factor: 3.845

Review 2.  The Diverse Contributions of Fucose Linkages in Cancer.

Authors:  Tyler S Keeley; Shengyu Yang; Eric Lau
Journal:  Cancers (Basel)       Date:  2019-08-24       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.